Working with TipRanks
Follow Us
Stocks
ETFs
Options
Commodities
Crypto
Currency
Pro Newsletters
Research Tools
Calendars
Economic Indicators
Class Actions
Calculators
Education
About Us
Working with TipRanks
Follow Us
Myriad Genetics (MYGN)
NASDAQ:MYGN
Holding MYGN?
Track your performance easily
MYGN Stock Chart & Stats
Day’s Range$0 - $0
52-Week Range$14.77 - $29.30
Previous Close$15
Volume755.99K
Average Volume (3M)781.51K
Market Cap
$1.37B
Enterprise Value$1.41B
Total Cash (Recent Filing)$99.90M
Total Debt (Recent Filing)$143.10M
Price to Earnings (P/E)―
Beta2.12
Next Earnings
Mar 04, 2025EPS Estimate
$0.03Last Dividend Ex-Date
Jun 15, 2009Dividend YieldN/A
Share Statistics
EPS (TTM)-1.30
Shares Outstanding91,035,230
10 Day Avg. Volume1,053,796
30 Day Avg. Volume781,507
Standard Deviation0.16
R-Squared0.39
Alpha-0.02
Financial Highlights & Ratios
Price to Book (P/B)1.90
Price to Sales (P/S)1.66
Price to Cash Flow (P/CF)487.70
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/Revenue1.71
Enterprise Value/Gross Profit2.72
Enterprise Value/Ebitda-45.89
Forecast
1Y Price Target
$25.70Price Target Upside67.97% Upside
Rating ConsensusHold
Number of Analyst Covering10
Myriad Genetics News
Bulls Say, Bears Say
Bulls Say
Financial PerformancePricing improvements across the portfolio have made ASPs stable, removing them as a headwind and contributing positively to the company's financial health.
Growth StrategyMYGN provided a positive recap of its ongoing transformation & strategy to drive accelerated profitable growth in its existing under-penetrated channels.
Investment PotentialValuation is compelling with shares now at a significant discount to peers, suggesting attractive investment potential.
Bears Say
Coverage And ReimbursementThe decision by UNH to update its medical policy on GeneSight is expected to be a headwind, as UNH's GeneSight revenues account for about 5% of Myriad Genetics' total revenues.
Financial PerformanceThe total revenue of $213.3M, while growing 11.2% year-over-year, was achieved with an out-of-period collection benefit, and excluding this, most revenue line items were lighter than expected.
Research And DevelopmentManagement did not provide any new data readouts for the MRD test, and the commercial launch has been pushed out to 2026.
---
Ownership Overview
3.51% Insiders
25.28% Mutual Funds
22.43% Other Institutional Investors
20.53% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Finance & CorporateFinancial and accounting risks. Risks related to the execution of corporate activity and strategy
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
MYGN FAQ
What was Myriad Genetics’s price range in the past 12 months?
Myriad Genetics lowest stock price was $14.77 and its highest was $29.30 in the past 12 months.
What is Myriad Genetics’s market cap?
Currently, no data Available
When is Myriad Genetics’s upcoming earnings report date?
Myriad Genetics’s upcoming earnings report date is Mar 04, 2025 which is in 103 days.
How were Myriad Genetics’s earnings last quarter?
Myriad Genetics released its earnings results on Nov 07, 2024. The company reported $0.06 earnings per share for the quarter, beating the consensus estimate of $0.019 by $0.041.
Is Myriad Genetics overvalued?
According to Wall Street analysts Myriad Genetics’s price is currently Undervalued.
Does Myriad Genetics pay dividends?
Myriad Genetics pays a Notavailable dividend of $1.75 which represents an annual dividend yield of N/A. See more information on Myriad Genetics dividends here
What is Myriad Genetics’s EPS estimate?
Myriad Genetics’s EPS estimate is $0.03.
How many shares outstanding does Myriad Genetics have?
Myriad Genetics has 91,035,230 shares outstanding.
What happened to Myriad Genetics’s price movement after its last earnings report?
Myriad Genetics reported an EPS of $0.06 in its last earnings report, beating expectations of $0.019. Following the earnings report the stock price went down -1.471%.
Which hedge fund is a major shareholder of Myriad Genetics?
Among the largest hedge funds holding Myriad Genetics’s share is Glenview Capital Management LLC. It holds Myriad Genetics’s shares valued at 103M.
---
Myriad Genetics Stock Smart Score
Unlock Smart Score
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Hold
Average Price Target:
$25.70 (67.97% Upside)
$25.70 (67.97% Upside)
Blogger Sentiment
Bullish
MYGN Sentiment 100%
Sector Average 72%
Sector Average 72%
Insider Transactions
Sold Shares
Worth $646.4K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Positive
Last 7 Days ▼ 1.8%
Last 30 Days ▲ 4.4%
Last 30 Days ▲ 4.4%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-16.06%
12-Months-Change
Fundamentals
Return on Equity
-16.39%
Trailing 12-Months
Asset Growth
-5.90%
Trailing 12-Months
Company Description
Myriad Genetics
Myriad Genetics, Inc. engages in the discovery, development, and marketing of transformative molecular diagnostic test. It operates through the Diagnostics and Other segments. The Diagnostics segment provides testing and collaborative development of testing that is designed to asses an individual's risk of developing a disease later in life. The Other segment offers products and services to the pharmaceutical, biotechnology and medical research industries, research and development, and clinical services for patients; and also includes corporate services such as finance, human resources, legal, and information technology. The company was founded by Walter A. Gilbert, Mark H. Skolnick, and Peter D. Meldrum in May 1991 and is headquartered in Salt Lake City, UT.
---
MYGN Company Deck
---
MYGN Earnings Call
Q3 2024
0:00 / 0:00
---
MYGN Stock 12 Month Forecast
Average Price Target
$25.70
▲(67.97% Upside)
Technical Analysis
Best Analysts Covering MYGN
1 Year
1 Year Success Rate
5/8 ratings generated profit
1 Year Average Return
-2.21%
reiterated a sell rating 11 days ago
Copying Rachel Vatnsdal's trades and holding each position for 1 Year would result in 62.50% of your transactions generating a profit, with an average return of -2.21% per trade.
---